US Patent Issued to Amgen on Aug. 5 for "Method for enhancing production of genetically engineered autologous T cells" (California Inventor)

ALEXANDRIA, Va., Aug. 6 -- United States Patent no. 12,378,521, issued on Aug. 5, was assigned to Amgen Inc. (Thousand Oaks, Calif.).

"Method for enhancing production of genetically engineered autologous T cells" was invented by Yijun Liu (Camarillo, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a method for enhancing production of autologous genetically engineered T cells for use in cell therapy applications."

The patent was filed on April 13, 2021, under Application No. 17/228,843.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html...